SCHEMBL3534873

SCHEMBL3534873

CN1CCN(c2ccc3nc(-c4n[nH]c5cccc(COCc6ccccc6)c45)[nH]c3c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 13/20 0.62
FLT1 P17948 7/20 0.62
ABL1 P00519 4/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 1/20 0.49
BCR P11274 1/20 0.48
CDK4 P11802 1/20 0.48
CCNA2 P20248 1/20 0.48
CCND1 P24385 1/20 0.48
CDK2 P24941 1/20 0.48
CCND3 P30281 1/20 0.48
KDR P35968 5/20 0.47
PDGFRB P09619 4/20 0.47
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
FGFR2 P21802 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539715 0.89 FGFR1 (0.66) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3538567 0.87 FGFR1 (0.64) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2
SCHEMBL3541772 0.87 FGFR1 (0.74) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2
SCHEMBL3535489 0.86 FGFR1 (0.62) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2
SCHEMBL3536832 0.86 FGFR1 (0.79) FGFR1FLT1ABL1BCRKDR
SCHEMBL3536930 0.84 FGFR1 (0.70) FGFR1FLT1ABL1BCRCDK4
SCHEMBL3537770 0.84 FGFR1 (0.70) FGFR1FLT1ABL1BCRCDK4
SCHEMBL3537272 0.80 FGFR1 (0.71) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2
SCHEMBL3545063 0.80 FGFR1 (0.68) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2
SCHEMBL5866750 0.80 FGFR1 (0.71) FGFR1FLT1ABL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.